Characteristics of lofexidine in pharmacological screening.
Pharmacological and limited toxicological screening tests have been performed in order to provide an initial assessment of a new hypotensive substance, 2-[1-(2,6-dichlorphenoxy)-ethyl-2-imidazoline hydrochloride (lofexidine, Lofetensin and Loxacor). After intravenous and intraduodenal administration, this new delta 2-imidazoline compound caused a dose-related, long-lasting reduction of blood pressure. This effect was demonstrable with doses of only 1-10 microgram/kg (i.v.) and 6-60 microgram/kg (intraduodenally). The results suggest a clonidine-like mechanism of action and provided justification for more detailed pharmacological and toxicological studies.
D000818:Animals; D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D003000:Clonidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D003326:Coronary Circulation / Q000187:drug effects; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects*; D009092:Mucous Membrane / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D011674:Pulse / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects
D000959:Antihypertensive Agents; D003000:Clonidine; C025655:lofexidine